Core Insights - The "14th Five-Year Plan" period has seen significant reforms in drug and medical consumables procurement in Dezhou City, leading to substantial price reductions and alleviating the financial burden on the public [1][2] Group 1: Procurement Measures - The Dezhou Medical Security Bureau has implemented centralized procurement to drive supply-side reforms in the pharmaceutical sector, resulting in a substantial return to reasonable pricing for drugs and medical consumables [1] - A total of 20 batches of drugs (890 varieties) and 22 batches of consumables (43 categories) have been executed under the centralized procurement system, ensuring the availability of high-quality and affordable products [1] Group 2: Financial Mechanisms - The establishment of an optimized settlement mechanism has significantly shortened the payment cycle for pharmaceutical companies, with direct settlements amounting to 23,337 million yuan for drugs and 3,283 million yuan for medical consumables [2] - An incentive mechanism has been put in place to encourage medical institutions to actively participate in procurement, with 741,000 yuan allocated for drug procurement savings and 19,000 yuan for consumables [2] Group 3: Accessibility Initiatives - Efforts to extend centralized procurement services to grassroots levels have been made, with 16 designated hospitals, 70 village clinics, and 88 designated pharmacies now providing access to procured drugs [3] - The initiative aims to enhance the accessibility of quality and affordable medications for the community, ensuring that essential drugs are available at local healthcare facilities [3]

Core Viewpoint - The establishment of the Shandong-Hebei Provincial Emergency Critical Care Transfer Alliance aims to enhance regional emergency medical capabilities and response efficiency through a collaborative network of medical institutions [1][2] Group 1: Alliance Formation - The alliance was initiated by Qilu Hospital Dezhou Hospital under the guidance of the Dezhou Health Commission, breaking down provincial barriers to create a non-profit emergency critical care transfer network [1] - The alliance's mission is to promote standardized and homogenized emergency critical care, implement tiered diagnosis and treatment policies, and enhance the service capabilities of grassroots medical institutions [1] Group 2: Academic Exchange - The conference included academic discussions on critical care and transfer topics, featuring presentations from experts on various subjects, including the 2024 edition of the "Non-neonatal Tetanus Diagnosis and Treatment Guidelines" [1] - Notable contributions included case studies and management strategies related to emergency chest pain and sedation techniques for intubation in emergency settings [1] Group 3: Future Plans - Member units discussed the collaborative mechanism for transfer diagnosis and treatment, planning the next steps for the alliance [2] - The alliance aims to establish unified technical standards, clinical pathways, and management norms, along with a two-way referral mechanism to optimize and efficiently utilize medical resources in the region [2] - The goal is to create demonstration centers and training bases for emergency critical care, ultimately providing safer and more efficient medical services to the communities in the Shandong-Hebei region [2]

"希望女儿在海南治疗后能顺利实现'脱氧'。"此前，孩子母亲通过远程会诊与马明广取得联系，在远程 指导治疗下，患儿症状得到初步控制与改善。基于对该医疗团队的信任，她决定带子女赴琼接受进一步 系统评估与干预。该院在获悉航班信息后启动跨境患者绿色通道，安排医护随救护车赴机场接机，并于 入院当天组织儿科、呼吸、影像、营养及康复等多学科团队开展联合评估。 针对安安的气道高反应性与萌萌的氧依赖状态，马明广团队制定个体化方案，采用阶梯式呼吸支持策 略，结合呼吸康复训练、气道廓清技术及营养干预，并同步为母亲提供家庭护理指导与应急处理培训， 提升居家照护能力，助力这对兄妹逐步提升生活自主能力，早日实现脱氧自由呼吸。 马明广表示，此次治疗计划为期近两周，目标是在保障安全的前提下，推动兄妹逐步减少氧疗依赖。出 院后，医疗团队将通过远程随访平台持续跟踪生长发育、肺功能及感染防控情况，形成"短期集中干预 +长期线上护航"的跨境慢病管理模式，为境外慢肺患儿提供延续性管理支持。 该院慢肺中心成立1个多月来，已救治近20例国内外慢肺患儿。记者 钟起的 文/图 本报讯 一对新加坡的兄妹因早产导致支气管肺发育不良（BPD）进入慢性阶段，昨日上午 ...

每日经济新闻 （记者 曾健辉） 免责声明：本文内容与数据仅供参考，不构成投资建议，使用前请核实。据此操作，风险自担。 每经讯，荣恩集团12月30日发布公告称，根据公司发展规划，拟与罗慧萍女士在广东省佛山市合资设 立"佛山市荣恩综合门诊部有限公司"和"佛山市容恩医疗美容有限公司"。"佛山市荣恩综合门诊部有限 公司"注册资本200万元，公司出资130万元占比65%，罗慧萍女士出资70万元占比35%，出资方式为货 币出资。"佛山市容恩医疗美容有限公司"注册资本100万元，公司出资65万元占比65%，罗慧萍女士出 资35万元占比35%，出资方式为货币出资。公司于2025年12月30日召开第四届董事会第六次会议，审议 通过《注销并新设子公司暨关联交易的议案》，本议案无需提交股东会审议。 ...

Group 1 - The core point of the article is that Haijia Medical has been actively repurchasing its shares, with a total of 11 buybacks this year, amounting to 3.2734 million shares and a total expenditure of 42.2829 million HKD [2][3] - On December 30, the company repurchased 334,600 shares at a price range of 12.390 to 12.530 HKD, totaling 4.1648 million HKD, while the stock closed at 12.480 HKD, down 0.56% for the day [2] - Since December 29, the company has conducted buybacks for two consecutive days, repurchasing a total of 570,600 shares for a cumulative amount of 7.1624 million HKD, during which the stock price has decreased by 1.73% [2] Group 2 - The detailed buyback information shows that on December 29, 2025, the company repurchased 236,000 shares at a maximum price of 12.750 HKD and a minimum price of 12.540 HKD, totaling 2.9976 million HKD [3] - The buyback activities include various dates with different volumes and prices, indicating a strategic approach to managing share value [3] - The highest buyback price recorded this year was 14.140 HKD on January 2, 2025, while the lowest was 12.040 HKD on December 17, 2025 [3]

Core Viewpoint - Guangdong Province will implement a "one registration covers three days" policy for public medical institutions starting January 1, 2026, aimed at reducing patient costs and improving convenience in medical services [1][2]. Group 1: Policy Implementation - The "one registration covers three days" policy allows patients to receive a follow-up appointment within three days without additional registration fees if diagnostic results are not available on the same day [2]. - The policy will be applied to all public medical institutions in Guangdong, including traditional Chinese medicine and maternal and child health institutions, with encouragement for private medical institutions to adopt similar measures [1][2]. Group 2: Pilot Program Results - The pilot program, initiated in cities like Shenzhen, Zhuhai, and Guangzhou, has served nearly 7 million patients since its launch, demonstrating significant positive outcomes [3]. - In Shenzhen, over 500 million patients benefited from the policy, with diagnostic fees waived amounting to over 200 million yuan [3]. - Zhuhai implemented a similar policy allowing free follow-up appointments within a week, resulting in a fee reduction of nearly 13 million yuan [3].

Group 1 - The core viewpoint of the article is that International Medical has clarified its fundraising plan for the 2025 fiscal year, which will be used for specific projects and working capital [1] - The funds raised will be allocated to the Smart Health and Elderly Care Project, the Phase II Proton Therapy Center Project, and to supplement working capital [1] - The company emphasizes that the fundraising is compliant and does not involve any acquisition matters [1] Group 2 - The company assures that it strictly adheres to laws, regulations, and regulatory requirements to ensure proper corporate governance [1] - All significant matters will be disclosed in accordance with information disclosure rules in a timely manner [1] - For any external investments or asset acquisitions, the company advises stakeholders to refer to formal announcements published in designated information disclosure media [1]

广东将有序推行"一次挂号管三天" 中新网广州12月30日电 (记者 蔡敏婕)广东省卫生健康委30日发布消息称，自2026年1月1日起，广东公 立医疗机构将有序推开普通门诊"一次挂号管三天"惠民便民措施。此举旨在解决患者因检查检验结果未 当天出具而需反复挂号的问题，进一步节约民众就医成本，提升就医便利性。 什么是"一次挂号管三天"？当患者首次挂普通号看门诊时，接诊医生为明确当前的疾病诊断或病情进展 所开具医学检查、临床检验(以下简称检查检验)项目，因结果出具时间超出该医生当天坐诊时间范围， 而导致没能完成一次完整诊疗过程，医疗机构应配合患者预约一次近期的"续诊号"(一般为3个自然日 内)。 该次"续诊号"无需患者支付普通门诊挂号费，用于医生完成解读检查检验结果，以及后续开具药物和其 他医疗处置等行为，以保证患者能够获得一次完整诊疗。 一次挂号只管"三天"吗？三天内检查检验结果还没出来怎么办？广东省卫生健康委解释，一般为包括首 次就诊当天在内的3个自然日。如有特殊检查检验结果出具时间较长的，各医院可结合实际情况在3天的 基础上自行规定时限。 哪些情况不能享受"一次挂号管三天"？广东省卫生健康委指出，首次就诊当次诊 ...

美丽田园医疗健康(02373)发布公告，于2025年12月30日，为有效利用闲置资金，集团的非全资附属公 司北京贝黎诗根据12月30日认购自浦发银行认购总金额为人民币8000万元的保本理财产品。 此外，公司通过北京贝黎诗及上海美丽田园医疗健康，(i)于2025年11月28日根据11月28日认购自浦发银 行认购金额为人民币1000万元;(ii)于2025年11月21日根据11月21日认购自浦发银行认购金额为人民币 7000万元;(iii)于2025年10月9日根据10月9日认购自浦发银行认购金额为人民币8000万元的保本理财产 品，上述所有产品于本公告日期均仍尚未到期。 ...

Core Viewpoint - Meili Tianyuan Medical Health (02373.HK) announced the investment of idle funds into principal-protected financial products from Pudong Development Bank, totaling RMB 80 million as of December 30, 2025 [1] Group 1: Investment Details - The company, through Beijing Beilish and Shanghai Meili Tianyuan Medical Health, subscribed to a principal-protected financial product from Pudong Development Bank for RMB 10 million on November 28, 2025 [1] - Additionally, the company subscribed for RMB 70 million on November 21, 2025, and RMB 80 million on October 9, 2025, all from Pudong Development Bank [1] - All aforementioned financial products remain outstanding as of the announcement date [1]